The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Abstract
The presence of multidrug resistance (MDR) in malignant tumors is one of the primary causes of treatment failure in cancer chemotherapy. The overexpression of the ATP binding cassette (ABC) transporter, P-glycoprotein (P-gp), which significantly increases the efflux of certain anticancer drugs from tumor cells, produces MDR. Therefore, inhibition of P-gp may represent a viable therapeutic strategy to overcome cancer MDR. Over the past 4 decades, many compounds with P-gp inhibitory efficacy (referred to as first- and second-generation P-gp inhibitors) have been identified or synthesized. However, these compounds were not successful in clinical trials due to a lack of efficacy and/or untoward toxicity. Subsequently, third- and fourth-generation P-gp inhibitors were developed but dedicated clinical trials did not indicate a significant therapeutic effect. In recent years, an extraordinary array of highly potent, selective, and low-toxicity P-gp inhibitors have been reported. Herein, we provide a comprehensive review of the synthetic and natural products that have specific inhibitory activity on P-gp drug efflux as well as promising chemosensitizing efficacy in MDR cancer cells. The present review focuses primarily on the structural features, design strategies, and structure-activity relationships (SAR) of these compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mohana, S., Ganesan, M., Prasad, N. R., Ananthakrishnan, D., & Velmurugan, D. (2018) · BMC Cancer · doi:10.1186/s12885-018-5103-1 · Cited by 38
RetractedMultidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Medicinal attributes of 1,2,3-triazoles: Current developments
Dheer, D., Singh, V., & Shankar, R. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.01.010 · Cited by 873
The 1,2,3-triazole ring as a bioisostere in medicinal chemistry
Bonandi, E., Christodoulou, M. S., Fumagalli, G., Perdicchia, D., Rastelli, G., & Passarella, D. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.05.014 · Cited by 743
Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Self-citationLi, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Self-citationModulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Self-citationSzakács, G., Váradi, A., Özvegy-Laczka, C., & Sarkadi, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.010 · Cited by 569
Oral bioavailability of curcumin: problems and advancements
Liu, W., Zhai, Y., Heng, X., Che, F. Y., Chen, W., Sun, D., & Zhai, G. (2016) · Journal of Drug Targeting · doi:10.3109/1061186x.2016.1157883 · Cited by 566
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Palmeira, A., Sousa, E., H. Vasconcelos, M., & M. Pinto, M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167392 · Cited by 484
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Structural insight into substrate and inhibitor discrimination by human P-glycoprotein
Alam, A., Kowal, J., Broude, E., Roninson, I., & Locher, K. P. (2019) · Science · doi:10.1126/science.aav7102 · Cited by 469
Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 437
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement
Varma, M. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00158-0 · Cited by 418
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment: Miniperspective
Waghray, D., & Zhang, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01457 · Cited by 400
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Qin, J.-J., Yan, L., Zhang, J., & Zhang, W.-D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1206-z · Cited by 396
Self-citationBinkhathlan, Z., & Lavasanifar, A. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990076 · Cited by 390
Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0499 · Cited by 386
Self-citationPlant flavonoids in cancer chemoprevention: role in genome stability
George, V. C., Dellaire, G., & Rupasinghe, H. P. V. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.11.007 · Cited by 362
(2001) · PubMed · Cited by 350
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
Molecular basis of antifolate resistance
Assaraf, Y. G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9049-z · Cited by 338
Natural products as multidrug resistance modulators in cancer
Kumar, A., & Jaitak, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.027 · Cited by 334
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Self-citationP-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review
Abdallah, H. M., Al-Abd, A. M., El-Dine, R. S., & El-Halawany, A. M. (2015) · Journal of Advanced Research · doi:10.1016/j.jare.2014.11.008 · Cited by 319
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols
Jodoin, J., Demeule, M., & Béliveau, R. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(01)00175-6 · Cited by 300
Anuchapreeda, S., Leechanachai, P., Smith, M. M., Ambudkar, S. V., & Limtrakul, P.-N. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01224-8 · Cited by 291
Flavonoid–drug interactions: Effects of flavonoids on ABC transporters
Morris, M. E., & Zhang, S. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.003 · Cited by 273
Riganti, C., Miraglia, E., Viarisio, D., Costamagna, C., Pescarmona, G., Ghigo, D., & Bosia, A. (2005) · Cancer Research · doi:10.1158/0008-5472.516.65.2 · Cited by 271
Ward, A. B., Szewczyk, P., Grimard, V., Lee, C.-W., Martinez, L., Doshi, R., Caya, A., Villaluz, M., Pardon, E., Cregger, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309275110 · Cited by 256
Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects
Khan, H., Ullah, H., Martorell, M., Valdes, S. E., Belwal, T., Tejada, S., Sureda, A., & Kamal, M. A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.023 · Cited by 247
Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Bansal, T., Jaggi, M., Khar, R., & Talegaonkar, S. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3rc77 · Cited by 238
Chearwae, W., Anuchapreeda, S., Nandigama, K., Ambudkar, S. V., & Limtrakul, P. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.009 · Cited by 229
Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NFκB pathway
Choi, B. H., Kim, C. G., Lim, Y., Shin, S. Y., & Lee, Y. H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.10.003 · Cited by 217
Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy
Dixon, P. H., van Mil, S. W. C., Chambers, J., Strautnieks, S., Thompson, R. J., Lammert, F., Kubitz, R., Keitel, V, Glantz, A., Mattsson, L.-Å., et al. (2009) · Gut · doi:10.1136/gut.2008.159541 · Cited by 215
Inhibition of P-Glycoprotein Function and Expression by Kaempferol and Quercetin
Limtrakul, P., Khantamat, O., & Pintha, K. (2005) · Journal of Chemotherapy · doi:10.1179/joc.2005.17.1.86 · Cited by 210
Rationally designed nanovehicles to overcome cancer chemoresistance
Livney, Y. D., & Assaraf, Y. G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.006 · Cited by 205
(2011) · Advances in Clinical Chemistry · doi:10.1016/b978-0-12-385855-9.00007-2 · Cited by 204
Cancer chemoprevention through dietary flavonoids: what’s limiting?
Amawi, H., Ashby, C. R., & Tiwari, A. K. (2017) · Chinese Journal of Cancer · doi:10.1186/s40880-017-0217-4 · Cited by 204
Self-citationMolecular mechanisms of drug resistance in ovarian cancer
Norouzi‐Barough, L., Sarookhani, M. R., Sharifi, M., Moghbelinejad, S., Jangjoo, S., & Salehi, R. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26289 · Cited by 200
Leonetti, A., Wever, B., Mazzaschi, G., Assaraf, Y. G., Rolfo, C., Quaini, F., Tiseo, M., & Giovannetti, E. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100644 · Cited by 200
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Niewerth, D., Jansen, G., Assaraf, Y. G., Zweegman, S., Kaspers, G. J. L., & Cloos, J. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.001 · Cited by 189
Borgnia, M. J., Eytan, G. D., & Assaraf, Y. G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.6.3163 · Cited by 180
Drori, S., Eytan, G. D., & Assaraf, Y. G. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.1020m.x · Cited by 179
Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer
Joshi, P., Vishwakarma, R. A., & Bharate, S. B. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.047 · Cited by 174
Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Cao, X., Hou, J., An, Q., Assaraf, Y. G., & Wang, X. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100671 · Cited by 172
Regev, R., Assaraf, & Eytan, G. D. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00037.x · Cited by 171
Boumendjel, A., Di Pietro, A., Dumontet, C., & Barron, D. (2002) · Medicinal Research Reviews · doi:10.1002/med.10015 · Cited by 162
Nile, S. H., Keum, Y. S., Nile, A. S., Jalde, S. S., & Patel, R. V. (2017) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22002 · Cited by 161
Recent Advances in the Development of Indazole‐based Anticancer Agents
Dong, J., Zhang, Q., Wang, Z., Huang, G., & Li, S. (2018) · ChemMedChem · doi:10.1002/cmdc.201800253 · Cited by 161
Self-citationde Vries, N. A., Buckle, T., Zhao, J., Beijnen, J. H., Schellens, J. H. M., & van Tellingen, O. (2012) · Investigational New Drugs · doi:10.1007/s10637-010-9569-1 · Cited by 158
Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1
Gutmann, D. A. P., Ward, A. B., Urbatsch, I. L., Chang, G. A., & van Veen, H. W. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.07.009 · Cited by 152
Redundant angiogenic signaling and tumor drug resistance
Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 144
Effect of Flavonoids on MRP1-Mediated Transport in Panc-1 Cells
Nguyen, H. T. T., Zhang, S., & Morris, M. E. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10283 · Cited by 131
Karthikeyan, S., & Hoti, S. L. (2015) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150113103439 · Cited by 123
Qin, J., Li, X., Hunt, C., Wang, W., Wang, H., & Zhang, R. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.07.002 · Cited by 117
Self-citationEytan, G. D., Regev, R., Oren, G., Hurwitz, C. D., & Assaraf, Y. G. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00104.x · Cited by 115
Inulasesquiterpenoids: structural diversity, cytotoxicity and anti-tumor activity
Wang, G., Qin, J., Cheng, X., Shen, Y., Shan, L., Jin, H., & Zhang, W. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.868882 · Cited by 111
Self-citationChan, K., Zhao, Y., Burkett, B. A., Wong, I. L. K., Chow, L. M. C., & Chan, T. H. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060593+ · Cited by 103
Specific Inhibitors of the Breast Cancer Resistance Protein (BCRP)
Pick, A., Klinkhammer, W., & Wiese, M. (2010) · ChemMedChem · doi:10.1002/cmdc.201000216 · Cited by 102
Zhang, Y., Wang, S., Ma, J., Li, H., Ye, J., Xie, S., Du, B., & Zhong, X. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1604-1 · Cited by 100
Mohana, S., Muthusamy, G., Balupillai, A., Karthikeyan, R., Gunaseelan, S., Mary, R. B., Ananthakrishnan, D., Velmurugan, D., Prasad, N. R., & Ambudkar, S. V. (2016) · Molecular BioSystems · doi:10.1039/c6mb00187d · Cited by 96
Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review
Qin, J., Cheng, X., Zhang, J., & Zhang, W. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0435-2 · Cited by 96
Self-citationLiu, X., Tee, H.-W., & Go, M. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.006 · Cited by 95
Chen, T., Wang, C., Liu, Q., Meng, Q., Sun, H., Huo, X., Sun, P., Peng, J., Liu, Z., Yang, X., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.987062 · Cited by 94
Targeting MDM2 for novel molecular therapy: Beyond oncology
Wang, W., Qin, J., Rajaei, M., Li, X., Yu, X., Hunt, C., & Zhang, R. (2019) · Medicinal Research Reviews · doi:10.1002/med.21637 · Cited by 91
Self-citationSui, H. X., Cai, G.-X., Pan, S.-F., Deng, W.-L., Wang, Y., Chen, Z., Cai, S.-J., Zhu, H.-R., & Li, Q. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0167 · Cited by 89
Self-citationChufán, E. E., Kapoor, K., & Ambudkar, S. V. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.007 · Cited by 89
Bai, J., Zhao, S., Fan, X., Chen, Y., Zou, X., Hu, M., Wang, B., Jin, J., Wang, X., Hu, J., et al. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.02.010 · Cited by 88
Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer
Joice, G. A., Bivalacqua, T. J., & Kates, M. R. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0220-4 · Cited by 85
Chen, M., Huang, S., Zhang, X., Zhang, B., Zhu, H., Yang, V. W., & Zou, X. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24122 · Cited by 83
Bai, Z., Gao, M., Zhang, H., Guan, Q., Xu, J., Li, Y., Qi, H., Li, Z., Zuo, D., Zhang, W., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.016 · Cited by 83
Self-citationInhibitory Effects of Polyphenols on P-Glycoprotein-Mediated Transport
Kitagawa, S. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.1 · Cited by 82
Bar-Zeev, M., Assaraf, Y. G., & Livney, Y. D. (2016) · Oncotarget · doi:10.18632/oncotarget.8019 · Cited by 81
Péter, B., Bősze, S. E., & Horváth, R. (2016) · European Biophysics Journal · doi:10.1007/s00249-016-1141-2 · Cited by 81
Chan, K., Wong, I. L. K., Kan, J. W. Y., Yan, C. S. W., Chow, L. M. C., & Chan, T. H. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201121b · Cited by 71
Ai, Y., Kang, F., Huang, Z., Xue, X., Lai, Y., Peng, S., Tian, J., & Zhang, Y. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5019302 · Cited by 71
Jekerle, V., Klinkhammer, W., Scollard, D. A., Breitbach, K., Reilly, R. M., Piquette‐Miller, M., & Wiese, M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21827 · Cited by 70
Teng, Y., Sheu, M., Hsieh, Y., Wang, R., Chiang, Y., & Hung, C. (2016) · Phytomedicine · doi:10.1016/j.phymed.2016.01.008 · Cited by 70
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview
Arrigoni, E., Galimberti, S., Petrini, M., Danesi, R., & Paolo, A. D. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1215423 · Cited by 64
Lopes-Rodrigues, V., Oliveira, A., Correia‐da‐Silva, M., Pinto, M. M. M., Lima, R. T., Sousa, E., & Vasconcelos, M. H. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.023 · Cited by 63
Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
Maia, R. C., Vasconcelos, F. D. C., de Souza, P. S., & Rumjanek, V. M. (2018) · Molecules · doi:10.3390/molecules23010119 · Cited by 62
Zhang, P. Y., Wong, I. L. K., Yan, C. S. W., Zhang, X. Y., Jiang, T., Chow, L. M. C., & Wan, S. B. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100035c · Cited by 61
Singh, S., Prasad, N. R., Chufán, E. E., Patel, B. A., Wang, Y., Chen, Z., Ambudkar, S. V., & Talele, T. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401966m · Cited by 61
Self-citationKim, M. K., Choo, H., & Chong, Y. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500290c · Cited by 61
Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy
Wang, W., Qin, J., Voruganti, S., Nijampatnam, B., Velu, S. E., Ruan, K., Hu, M., Zhou, J., & Zhang, R. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3939 · Cited by 60
Self-citationCorrelation of binding efficacies of DNA to flavonoids and their induced cellular damage
Das, A., Majumder, D., & Saha, C. (2017) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2017.04.019 · Cited by 59
Ferreira, A., Pousinho, S., Fortuna, A. C., Falcão, A. C., & Alves, G. (2014) · Phytochemistry Reviews · doi:10.1007/s11101-014-9358-0 · Cited by 56
A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer
Coppola, S., Carnevale, I., Danen, E. H. J., Peters, G. J., Schmidt, T., Assaraf, Y. G., & Giovannetti, E. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.07.001 · Cited by 56
Silbermann, K., Shah, C. P., Sahu, N. U., Juvale, K., Stefan, S. M., Kharkar, P. S., & Wiese, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.019 · Cited by 56
Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives
Li, X., Wang, L., Lei, Y., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.06.049 · Cited by 55
Gatouillat, G., Magid, A. A., Bertin, É., Btaouri, H. E., Morjani, H., Lavaud, C., & Madoulet, C. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.09.005 · Cited by 55
Chan, K., Zhao, Y., Chow, T. W., Yan, C. S. W., Ma, D., Burkett, B. A., Wong, I. L. K., Chow, L. M. C., & Chan, T. H. (2009) · ChemMedChem · doi:10.1002/cmdc.200800413 · Cited by 54
Mao, Z., Zhou, J., Luan, J., Sheng, W., Shen, X., & Dong, X. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.10.003 · Cited by 53
Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein
Fruttero, R., Crosetti, M., Chegaev, K. Y., Guglielmo, S., Gasco, A., Berardi, F., Niso, M., Perrone, R., Panaro, M. A., & Colabufo, N. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100066y · Cited by 53
Chen, H.-J., Chung, Y.-L., Li, C.-Y., Chang, Y., Wang, C. C. N., Lee, H.-Y., Lin, H., & Hung, C. (2018) · Molecules · doi:10.3390/molecules23123055 · Cited by 53
MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53
Wang, W., Cheng, J., Qin, J., Hu, B., Li, X., Nijampatnam, B., Velu, S. E., Fan, J., Yang, X., & Zhang, R. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.114429 · Cited by 53
Self-citationWong, I. L. K., Wang, B.-C., Yuan, J., Duan, L.-X., Liu, Z., Liu, T., Li, X., Hu, X., Zhang, X., Jiang, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00085 · Cited by 50
Zhang, Y.-T. Y., Zhu, X., Huang, T., Chen, L., Liu, Y., Li, Q., Song, J., Ma, S., Zhang, K., Yang, B., et al. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.08.010 · Cited by 50
Qiu, Q., Liu, B., Cui, J. H., Li, Z., Deng, X., Qiang, H., Li, J., Liao, C., Zhang, B., Shi, W., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01787 · Cited by 49
Tenacigenin B Derivatives Reverse P-Glycoprotein-Mediated Multidrug Resistance inHepG2/Dox Cells
Hu, Y., Shen, X., Lu, H.-L., et al. (2008) · Journal of Natural Products · doi:10.1021/np070458f · Cited by 48
P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update
Yang, X., & Liu, K. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666160629112717 · Cited by 48
Ranjbar, S., Khonkarn, R., Moréno, A., Baubichon-Cortay, H., Miri, R., Khoshneviszadeh, M., Saso, L., Edraki, N., Falson, P., & Firuzi, O. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.10.025 · Cited by 48
Transport of polypeptide ionophores into proteoliposomes reconstituted with rat liver P-glycoprotein
Eytan, G. D., Borgnia, M. J., Regev, R., et al. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47159-1 · Cited by 47
Structure–Activity Relationships of Tariquidar Analogs as Multidrug Resistance Modulators
Pajeva, I. K., & Wiese, M. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9118-z · Cited by 44
Yin, H., Dong, J., Cai, Y., Shi, X., Wang, H., Liu, G., Tang, Y., Liu, J., & Ma, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.053 · Cited by 44
Self-citationDong, J., Wang, Z., Cui, J., Meng, Q., & Li, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111938 · Cited by 43
Self-citationZhu, X., Wong, I. L. K., Chan, K., Cui, J., Law, M. C., Chong, T. C., Hu, X., Chow, L. M. C., & Chan, T. H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00963 · Cited by 42
Marine Natural Products as Models to Circumvent Multidrug Resistance
Long, S., Sousa, E., Kijjoa, A., & Pinto, M. M. M. (2016) · Molecules · doi:10.3390/molecules21070892 · Cited by 41
Gu, X., Ren, Z., Tang, X., Peng, H., Yuan-fang Ma, A., Lai, Y., Peng, S., & Zhang, Y. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.02.050 · Cited by 40
Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization
Obreque-Balboa, J. E., Sun, Q., Bernhardt, G., König, B., & Buschauer, A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.010 · Cited by 39
Gu, X., Huang, Z., Ren, Z., Tang, X., Xue, R., Luo, X., Peng, S., Peng, H., Lü, B., Tian, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01075 · Cited by 39
Qiu, Q., Shi, W., Li, Z., Zhang, B., Pan, M., Cui, J. H., Dai, Y., Huang, W., & Qian, H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01879 · Cited by 39
Identification of new P-glycoprotein inhibitors derived from cardiotonic steroids
Zeino, M., Paulsen, M. S., Zehl, M., Urban, E., Kopp, B., & Efferth, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.009 · Cited by 38
Pellicani, R. Z., Stefanachi, A., Niso, M., Carotti, A., Leonetti, F., Nicolotti, O., Perrone, R., Berardi, F., Cellamare, S., & Colabufo, N. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201305y · Cited by 38
Thonghin, N., Collins, R. F., Barbieri, A., Shafi, T., Siebert, C. A., & Ford, R. C. (2018) · BMC Structural Biology · doi:10.1186/s12900-018-0098-z · Cited by 36
Bharate, J. B., Singh, S., Wani, A., Sharma, S., Joshi, P., Khan, I. A., Kumar, A., Vishwakarma, R. A., & Bharate, S. B. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00246j · Cited by 35
Riganti, C., Contino, M., Guglielmo, S., Perrone, M. G., Salaroglio, I. C., Milosevic, V., Giampietro, R., Leonetti, F., Rolando, B., Lazzarato, L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01655 · Cited by 33
Gu, X., Ren, Z., Tang, X., Peng, H., Zhao, Q. J., Lai, Y., Peng, S., & Zhang, Y. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.02.034 · Cited by 32
Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells
Guberović, I., Marjanović, M., Mioč, M., Ester, K., Martin‐Kleiner, I., Ramljak, T. Š., Mlinarić‐Majerski, K., & Kralj, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-32770-y · Cited by 32
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
Qin, J., Wang, W., Sarkar, S., Voruganti, S., Agarwal, R., & Zhang, R. (2016) · Oncotarget · doi:10.18632/oncotarget.8873 · Cited by 31
Self-citationAssaraf, Y. G., & Borgnia, M. J. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb18928.x · Cited by 30
C-7 Analogues of Progesterone as Potent Inhibitors of the P-Glycoprotein Efflux Pump
Leonessa, F., Kim, J.-H., Ghiorghis, A., Kulawiec, R. J., Hammer, C. F., Talebian, A., & Clarke, R. C. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010126m · Cited by 28
Mudududdla, R., Guru, S. K., Wani, A., Sharma, S., Joshi, P., Vishwakarma, R. A., Kumar, A., Bhushan, S., & Bharate, S. B. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00233h · Cited by 28
Qin, J., Wang, W., Voruganti, S., Wang, H., Zhang, W., & Zhang, R. (2015) · Oncotarget · doi:10.18632/oncotarget.5851 · Cited by 28
Self-citationChen, C., Liu, N.-Y., Lin, H., Lee, C.-Y., Hung, C., & Chang, C. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.070 · Cited by 28
Kairuki, M., Qiu, Q., Pan, M., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.06.013 · Cited by 27
Development of benzochalcone derivatives as selective CYP1B1 inhibitors and anticancer agents
Dong, J., Huang, G., Zhang, Q., Wang, Z., Cui, J., Wu, Y. F., Meng, Q., & Li, S. (2019) · MedChemComm · doi:10.1039/c9md00258h · Cited by 27
Self-citationWen, Y., Zhao, R.-Q., Gupta, P., Fan, Y., Zhang, Y., Huang, Z., Li, X., Su, Y., Liao, L., Xie, Y.-A., et al. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.10.001 · Cited by 26
Self-citationDei, S., Coronnello, M., Floriddia, E., Bartolucci, G., Bellucci, C., Guandalini, L., Manetti, D., Romanelli, M. N., Salerno, M., Bello, I., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.084 · Cited by 25
Martelli, C., Coronnello, M., Dei, S., Manetti, D., Orlandi, F., Scapecchi, S., Romanelli, M. N., Salerno, M., Mini, E., & Teodori, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9016174 · Cited by 25
Tardia, P., Stefanachi, A., Niso, M., Stolfa, D. A., Mangiatordi, G. F., Alberga, D., Nicolotti, O., Lattanzi, G., Carotti, A., Leonetti, F., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500697c · Cited by 25
Dinić, J., Podolski-Renić, A., Jovanović, M., Musso, L., Tsakovska, I., Pajeva, I. K., Dallavalle, S., & Pešić, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184575 · Cited by 25
Liu, B., Qiu, Q., Zhao, T., Jiao, L., Hou, J., Li, Y., Qian, H., & Huang, W. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12301 · Cited by 24
Ranjbar, S., Firuzi, O., Edraki, N., Shahraki, O., Saso, L., Khoshneviszadeh, M., & Miri, R. (2017) · MedChemComm · doi:10.1039/c7md00178a · Cited by 23
Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells
Liu, W., Meng, Q., Sun, Y., Wang, C., Huo, X., Liu, Z., Sun, P., Sun, H., Ma, X., & Liu, K. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495650 · Cited by 22
Xanthone analogues as potent modulators of intestinal P-glycoprotein
Chae, S. W., Woo, S., Park, J. H., Kwon, Y., Na, Y., & Lee, H. J. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.006 · Cited by 21
Contino, M., Guglielmo, S., Perrone, M. G., Giampietro, R., Rolando, B., Carrieri, A., Zaccaria, D., Chegaev, K. Y., Borio, V., Riganti, C., et al. (2018) · MedChemComm · doi:10.1039/c8md00075a · Cited by 20
Shvarev, D., & Maldener, I. (2018) · FEMS Microbiology Letters · doi:10.1093/femsle/fny012 · Cited by 19
Rullo, M., Niso, M., Pisani, L., Carrieri, A., Colabufo, N. A., Cellamare, S., & Altomare, C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.043 · Cited by 18
Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport
Patel, A. S., Li, T., Anreddy, N., Wang, D., Sodani, K. S., Gadhia, S. R., Kathawala, R. J., Yang, D., Cheng, C., & Chen, Z. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.025 · Cited by 17
Self-citationCheon, J. H., Kim, J. Y., Lee, B., Kim, H. S., & Yoon, S. (2017) · Anticancer Research · doi:10.21873/anticanres.12136 · Cited by 17
Martelli, C., Dei, S., Lambert, C., Manetti, D., Orlandi, F., Romanelli, M. N., Scapecchi, S., Salerno, M., & Teodori, E. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.059 · Cited by 15
Intestinal P-glycoprotein inhibitors, benzoxanthone analogues
Chae, S. W., Lee, J., Park, J. H., Kwon, Y., Na, Y., & Lee, H. J. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12832 · Cited by 15
Li, G., Hu, X., Sun, L., Li, X., Li, J., Li, T., & Zhang, X. (2018) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-017-0067-8 · Cited by 15
Gu, X., Ren, Z., Peng, H., Peng, S., & Zhang, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.016 · Cited by 14
Teodori, E., Dei, S., Coronnello, M., Floriddia, E., Bartolucci, G., Manetti, D., Romanelli, M. N., Porqueras, D. S. D., & Salerno, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.01.019 · Cited by 14
Pati, M. L., Abate, C., Contino, M., Ferorelli, S., Luisi, R., Carroccia, L., Niso, M., & Berardi, F. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.001 · Cited by 13
Qiu, Q., Shi, W., Zhao, S.-Y., Zhu, Y., Ding, Z., Zhou, S., Kairuki, M., Huang, W., & Qian, H. (2019) · Archiv der Pharmazie · doi:10.1002/ardp.201900127 · Cited by 13
Titov, A. А., Niso, M., de Candia, M., Kobzev, M. S., Varlamov, A. V., Borisova, T. N., Voskressensky, L. G., Colabufo, N. A., Cellamare, S., Pisani, L., et al. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0037 · Cited by 12
Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors
Pan, M., Cui, J. H., Jiao, L., Ghaleb, H., Liao, C., Zhou, J., Kairuki, M., Lin, H., Huang, W., & Qian, H. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.015 · Cited by 11
Qiu, Q., Zhu, J., Chen, Q., Jiang, Z., Xu, J., Jiang, X., Huang, W., Liu, Z., Ye, J., & Xu, X. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103083 · Cited by 8
Cited by
Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies
Catalano, A., Iacopetta, D., Ceramella, J., Scumaci, D., Giuzio, F., Saturnino, C., Aquaro, S., Rosano, C., & Sinicropi, M. S. (2022) · Molecules · doi:10.3390/molecules27030616 · Cited by 450
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Duan, C., Yu, M., Xu, J., Li, B.-Y., Zhao, Y., & Kankala, R. K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114643 · Cited by 335
Yuan, L., Xu, Z.-Y., Ruan, S.-M., Mo, S., Qin, J.-J., & Cheng, X.-D. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01219-0 · Cited by 329
Self-citationPROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Qi, S.-M., Dong, J., Xu, Z.-Y., Cheng, X.-D., Zhang, W.-D., & Qin, J.-J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.692574 · Cited by 292
Self-citation
Metadata
- Authors
- Dong, J., Qin, Z., Zhang, W.-D., Cheng, G., Yehuda, A. G., Ashby, C. R., Chen, Z.-S., Cheng, X.-D., & Qin, J.-J.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 49
- Pages
- 100681
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W3002485806
- Cited by
- 255
- References
- 157
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.